A Pilot Study of Evidence-based Guided Self-help for the Treatment of Binge Eating

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05143866
Collaborator
National Eating Disorders Association (Other)
30
1
1
22.5
1.3

Study Details

Study Description

Brief Summary

The purpose of the present pilot study is to evaluate the feasibility, acceptability and likely effectiveness of an evidence-based guided self-help intervention for binge eating and related disordered over-eating in those unable to access clinician provided treatments. If feasible, acceptable and likely to be effective, such interventions could be made available more widely as an early intervention to those in need. Such interventions have the potential to improve quality of life by removing or ameliorating symptoms that impair psychological and social functioning. Eligible participants will receive the guided self-help intervention - an evidence-based self help program in the form of a self-help book plus telephone support and encouragement to follow the program provided by specially trained help-line volunteers. Support completing the self-help program will be provided over a period of 4 months and participants will be followed up for a year after completion of the intervention. Participants will be asked to complete brief online assessments before starting the program, at the end of 4 months when they complete the program and at 6 month and 12 month follow up.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive behavioral therapy guided self help (CBTgsh)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Feasibility with pre post assessmentFeasibility with pre post assessment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Closing the Treatment Gap: A Pilot Study of Evidence-based Guided Self-Help for the Treatment of Binge Eating and Related Disordered Eating
Actual Study Start Date :
Feb 15, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Self-help CBT

Evidence based book detailing self-help program to follow plus Telephone support from a non specialist guide

Behavioral: Cognitive behavioral therapy guided self help (CBTgsh)
Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide

Outcome Measures

Primary Outcome Measures

  1. Feasibility of providing intervention-consent [week 0 (baseline)]

    Percentage of eligible participants who consent to intervention

  2. Feasibility of providing intervention-completion Participants' ratings of satisfaction with the intervention [16 weeks]

    Percentage of eligible participants who complete intervention

  3. Ratings of Acceptability of intervention to participants [At Baseline - before start of intervention]

    Participants' ratings of suitability of intervention on visual analogue scale with anchors of strongly agree to strongly disagree

  4. Ratings of Acceptability of intervention to participants [16 weeks]

    Participants' ratings of suitability of intervention on visual analogue scale with anchors strongly agree to strongly disagree

  5. Ratings of Acceptability of intervention to participants [10 months]

    Participants' ratings of suitability of intervention on visual analogue scale with anchors strongly agree to strongly disagree

  6. Ratings of Acceptability of intervention to participants [16 months]

    Participants' ratings of suitability of intervention on visual analogue scale with anchors strongly agree to strongly disagree

  7. Ratings of participants' satisfaction with intervention with anchors strongly agree to strongly disagree [16 weeks]

    Participants rating of satisfaction with intervention on visual analogue scale with anchors strongly agree to strongly disagree

  8. Ratings of participants' satisfaction with intervention [10 months]

    Participants rating of satisfaction with intervention on visual analogue scale with anchors strongly agree to strongly disagree

  9. Ratings of participants' satisfaction with intervention [16 months]

    Participants rating of satisfaction with intervention on visual analogue scale with anchors strongly agree to strongly disagree

Secondary Outcome Measures

  1. Likely effectiveness -Eating difficulties [week 0 (baseline) and week 16 (end of intervention)]

    Change in global score on a well validated self-report measure of eating disorder attitudes and behavior-Eating Disorder Questionnaire. Possible range from 0 - 6 where higher score indicates worse symptoms.

  2. Likely effectiveness -Eating difficulties [week 0 (baseline) and week 64 (48 weeks/1 year after end of intervention)]

    Change in global score on a well validated self-report measure of eating disorder attitudes and behavior-Eating Disorder Questionnaire. Possible range from 0 - 6 where higher score indicates worse symptoms.

  3. Likely effectiveness - impairment due to eating difficulties [Week 0 (baseline) and week 16 (end of intervention)]

    Change in impairment due to eating difficulties score on well validated self report measure the Clinical Impairment assessment (CIA). Possible scores range from 0 (no impairment ) to 48 (highest level of impairment).

  4. Likely effectiveness - impairment due to eating difficulties [Week 0 (baseline) and week 64 (48 weeks/1 year after end of intervention)]

    Change in impairment due to eating difficulties score on well validated self report measure the Clinical Impairment assessment (CIA). Possible scores range from 0 (no impairment ) to 48 (highest level of impairment).

  5. Likely effectiveness - depression [Week 0 and week 16 (end of intervention)]

    Change in depression scores on well validated self report measure, Patient Health Questionnaire (PHQ 9). Possible scores 0 (no depressed mood) to 27 (highest levels of depressive symptoms.

  6. Likely effectiveness - depression [Week 0 and week 64 (48 weeks/1 Year after end of intervention)]

    Change in depression scores on well validated self report measure, Patient Health Questionnaire (PHQ 9). Possible scores 0 (no depressed mood) to 27 (highest levels of depressive symptoms.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Participant contacted National Eating Disorder Association (NEDA) with binge eating problems or disordered overeating

  • Completed NEDA screen and study screen

  • Age 18 and over

  • Able to speak, understand and read English

  • Consenting to guided self-help and completing study assessments

Exclusion Criteria:
  • Currently receiving treatment for an eating disorder

  • Self-reported weight body mass index (BMI) <20

  • Reported self-induced vomiting, laxative or diuretic use (purging)

  • Reports suicidal ideation

  • Breast feeding or pregnant

  • Receiving treatment for co-existing psychiatric condition (e.g., bipolar disorder, psychotic illness, drug or alcohol dependence

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yale Medical School Department of Psychiatry New Haven Connecticut United States 06511

Sponsors and Collaborators

  • Yale University
  • National Eating Disorders Association

Investigators

  • Study Director: Gabe Gavito, MS, National Eating Disorders Association

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zafra Cooper, Professor of Psychiatry (adjunct), Yale University
ClinicalTrials.gov Identifier:
NCT05143866
Other Study ID Numbers:
  • 2000031521
First Posted:
Dec 3, 2021
Last Update Posted:
Feb 22, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 22, 2022